China is continuing to raise its profile behind Healthcare investing- a look back at the last few quarters reveals:
-In Q4 2019, Asia funding doubled from Q3 2019—to over $4B, compared to $7.5B in the States
-In Q4 2019 China deals rebounded while US Deals fell..China signed 542 Health deals in the last quarter of 2019
-Q4 2019 HC funding in China rose 32% compared to Q3 2019
-8 China HC Unicorns were valued over $1B, compared to 20 in the States; China dominates in the Medical Imaging and Oncology biotech startups
-US HC funding on a quarterly basis- has decreased since its high in Q2 2016 of nearly $10.2B
Source CB insights
In sum, China is still very much on the move, despite the global Virus headlines these days. It has been widely reported that 5 of the 12 most active healthcare VCs are now China based. Meanwhile their funding of genomic testing and AI Imaging hit all time highs-including the February announcement of Genetron Health going public…
